Article Text

Download PDFPDF

#563 Cervical cancer burden of turkiye in spite of a nation-based cervical cancer screening program
  1. Nazli Topfedaisi Özkan1,
  2. Sinem Ayse Duru Çöteli2,
  3. Murat Öz3,
  4. Ibrahim Yalçin4,
  5. Koray Aslan5,
  6. Hüseyin Akilli6,
  7. Zeliha Firat Cüylan7,
  8. Özgün Ceylan7,
  9. Mustafa sahin7,
  10. Sevki Göksun Gökulu8,
  11. Mürside Çevikoglu Killi8,
  12. Ilker Selçuk7,
  13. Kemal Güngördük9,
  14. Utku Akgör10,
  15. Osman Çelik11,
  16. Naim Ata11,
  17. Suayip Birinci11,
  18. Mehmet Mutlu Meydanli12 and
  19. Ali Ayhan6
  1. 1Liv Hospital, Ankara, Türkiye
  2. 2Etlik City Hospital, Ankara, Türkiye
  3. 3Memorial Ankara Hospital, Ankara, Türkiye
  4. 4Ondokuz Mayis University, Samsun, Türkiye
  5. 5Abdurrahman Yurtaslan Oncologyi Training and Research Hospital, Ankara, Turkey
  6. 6Baskent University Hospital, Ankara, Türkiye
  7. 7Ankara City Hospital, Ankara, Turkey
  8. 8Mersin University Medical Faculty, Mersin, Türkiye
  9. 9Sitki Koçman University, Mugla, Turkey
  10. 10Ankara Research and Training Hospital, Ankara, Turkey
  11. 11Ministry of Health, Ankara, Turkey
  12. 12Medical Point Hospital, Gaziantep, Turkey


Introduction/Background Objective: The objective of this study was to determine the cervical cancer burden in Turkey during a nation-based cervical cancer screening program.

Methodology Methods: The database of the Turkish Ministry of Health was searched in order to identify all consecutive cervical cancer patients during 1st Jan 2019 and 31th Dec 2019 for this retrospective, nationwide, cohort study. The incidence of cervical cancer and the 3-year overall survival of the patients were investigated.

Results Results: With an age-standardized incidence of 4.2/100.000, cervical cancer is the 10th most common cancer among women in Turkey. During the study period, 658.000 women were screened for cervical cancer and 2539 new cervical cases were detected nationwide. The median age of the patients was 53 (range, 20–94) years. Cervical biopsy revealed HSIL in 195 (7.7%) women before the final diagnosis and 1671 (65.8%) cases were associated with HPV 16/18. The histologic distribution of the cases were as follows: squamous cell carcinoma in 1972 (77.7%), adenocarcinoma in 380 (15.0%) and adenosquamous cell carcinoma in 54 (2.1%) women. Primary chemoradiation was applied as primary treatment in 1285 (50.6%) women whereas 1254 (49.4%) underwent surgery. There were 938 (74.8%) radical and 249 (19.8%) simple hysterectomies. With a median follow-up of 28 months, the 3-year overall survival rates were 92.7%, 89.8% and 83.6% for stage IB1, IB2 and IB3, respectively. The 3-year overall survival rate for stage IIB was 79.1%. According to histologic subtypes, the 3-year overall survival rates were 71.9%, 72.0%, and 70.9% for women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma, respectively.

Conclusion Conclusion: In spite of a 10-years’ experience of a nation-based cervical cancer screening program, cervical cancer still seems to represent an important tumor burden in Turkey.

Disclosures NONE

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.